Sida 1 från 26 resultat
This invention relates to novel compounds having useful pharmacological properties, to pharmaceutical compositions containing them, to a process and intermediates for their preparation, and to their use as pharmaceuticals.
UK Patent Applications, GB Nos. 2100259A and 2125398A describe benzoates and
FIELD OF THE INVENTION
This invention relates to derivatives of novel 4,5,6,7-tetrahydroimidazo[4,5-c]pyridinyl-6-carboxylic acid useful as potent and selective anti-emetic or anti-nausea agents, or both, for pre-operative, intra-operative, and post-operative use.
BACKGROUND OF THE INVENTION
Nausea
BACKGROUND OF THE INVENTION
This invention is concerned with compounds of structural formula I: ##STR1## wherein X is --CH.dbd.CH--, --CH.sub.2 --CH.sub.2 --, --CH.sub.2 --O--, --O--CH.sub.2 --, --S--CH.sub.2 --, --CH.sub.2 --S--, --S-- or --O--, and R is a 5- or 6-membered nitrogen heterocyclic
BACKGROUND OF THE INVENTION
This invention is concerned with compounds of structural formula I: ##STR1## wherein X is --CH.dbd.CH--, --CH.sub.2 --CH.sub.2 --, --CH.sub.2 --O--, --O--CH.sub.2 --, --S--CH.sub.2 --, --CH.sub.2 --S--, --S-- or --O--, and R is a 5- or 6-membered nitrogen heterocyclic
BACKGROUND OF THE INVENTION
1. Field of Invention
Novel 5-aminomethyl- and 5-hydroxymethyl-1-azabicyclo[3.2.1]octanes and 5-aminomethyl- and 5-hydroxymethyl-1-azabicyclo[3.3.1]nonanes are coupled with aryl carboxylic acids to obtain the corresponding amides and esters. These novel amides and esters,
BACKGROUND OF THE INVENTION
1. Field of Invention
Novel 5-aminomethyl- and 5-hydroxymethyl-1-azabicyclo[3.2.1]octanes and 5-aminomethyl-and 5 -hydroxymethyl-1-azabicyclo[3.3.1]nonanes are coupled with aryl carboxylic acids to obtain the corresponding amides and esters. These novel amides and esters,
BACKGROUND OF THE INVENTION
A variety of agents are presently under development as potential treatments for migraine headaches. For example, MDL-72222 (tropine 3,5-dichlorobenzoate) is reported to block the M-receptors for 5-hydroxytryptamine (5-HT), now referred to as 5-HT.sub.3 receptors, thereby
BACKGROUND OF THE INVENTION
A variety of agents are presently under development as potential treatments for migraine headaches. For example, MDL-72222 (tropine 3,5-dichlorobenzoate) is reported to block the M-receptors for 5-hydroxytryptamine (5-HT), now referred to as 5-HT.sub.3 receptors, thereby
BACKGROUND OF THE INVENTION
This invention relates to benzimidazolone carboxylic acid derivatives. These compounds have selective 5-HT.sub.4 receptor agonistic activity. The present invention also relates to a pharmaceutical composition, method of treatment and use, comprising the above derivatives
BACKGROUND OF THE INVENTION
This invention relates to benzimidazolone carboxylic acid derivatives. These compounds have selective 5-HT.sub.4 receptor agonistic activity. The present invention also relates to a pharmaceutical composition, method of treatment and use, comprising the above derivatives
BACKGROUND OF THE INVENTION
This invention relates to benzimidazolone carboxylic acid derivatives. These compounds have selective 5-HT.sub.4 receptor agonistic activity. The present invention also relates to a pharmaceutical composition, method of treatment and use, comprising the above derivatives
BACKGROUND OF THE INVENTION
The invention herein is directed to compounds and a method of treating gastrointestinal motility disorders of a mammal by administering to the mammal in need thereof a therapeutically effective amount of a compound disclosed herein or a pharmaceutically acceptable salt
BACKGROUND OF THE INVENTION
The invention herein is directed to compounds and a method of treating gastrointestinal motility disorders of a mammal by administering to the mammal in need thereof a therapeutically effective amount of a compound disclosed herein or a pharmaceutically acceptable salt
BACKGROUND OF THE INVENTION
The invention herein is directed to compounds and a method of treating gastrointestinal motility disorders of a mammal by administering to the mammal in need thereof a therapeutically effective amount of a compound disclosed herein or a pharmaceutically acceptable salt
BACKGROUND OF THE INVENTION
The invention herein is directed to compounds and a method of treating gastrointestinal motility disorders of a mammal by administering to the mammal in need thereof a therapeutically effective amount of a compound disclosed herein or a pharmaceutically acceptable salt